A Phase 4 interventional study of Melatonin 3 MG Oral Tablet in Obstructive Sleep Apnea of Adult, sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Phase 4, Interventional, and Treatment
The goal of this clinical trial is to learn if melatonin works to treat comorbid insomnia in adults with OSA and nocturnal non-dipping blood pressure pattern.
The main question it aims to answer is:
Does melatonin maintain sleep during night and recover the dipping blood pressure pattern?
The goal of this clinical trial is to learn if melatonin works to treat comorbid insomnia in adults with OSA and nocturnal non-dipping blood pressure pattern.
The main question it aims to answer is:
Does melatonin maintain sleep during night and recover the dipping blood pressure pattern?
Participants will:
Researchers will compare melatonin to the habitual treatment to see if melatonin works to treat insomnia and recover the dipping blood pressure pattern.
The medical problems that participants would have when taking melatonin are:
2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
This study's planned enrollment of 50 is close to the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran is the lead sponsor of 144 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1\. Group of participants receives an intervention/treatment considered to be usual care
Drug: Melatonin 3 MG Oral Tablet
2\. Group of participants receives oral Melatonin 3 mg/day during 30 days plus usual care
Drug: Melatonin 3 MG Oral Tablet
Participants with OSA and nocturnal non-dipping Blood Pressure will be randomly assigned to a treatment with melatonin 3mg/d or to receive only the usual care.
Also known as: Usual Care for participants with OSA and nocturnal non-dipping Blood Pressure
Melatonin at a dose of 3 mg before sleep time, after a period of 30 days changes the time awake after sleep onset (WASO), and recovers the dipper pattern of blood pressure
Wake after sleep onset (WASO) and non-dipper patter of Blood Pressure change after melatonin intake for 30 days
Time frame: 30 days
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran →